Thomas Melchardt

E-Mailt.melchardtsalkat

Publikationen pro Jahr

67 Originalarbeit (Zeitschrift)
35 publizierter Abstrakt (Zeitschrift)
13 Übersichtsarbeit
8 Letter to the editor
Mehr

3 Ergebnisse

Filter

2020

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T. (Erstautor/-in), Melchardt, T. (Erstautor/-in), Hufnagl, C. (Co-Autor/-in), Weiss, L. (Co-Autor/-in), Mittermair, C., Neureiter, D. (Co-Autor/-in), Klieser, E. (Co-Autor/-in), Rinnerthaler, G. (Co-Autor/-in), Roesch, S. (Co-Autor/-in), Gaggl, A. (Co-Autor/-in), Greil, R. (Co-Autor/-in) & Egle, A. (Letztautor/-in), 2020, in: PHARMACOGENOMICS J. 20, 2, S. 350
Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung
2019

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.
Krauth, M.-T., Burgstaller, S., Buxhofer-Ausch, V., Gastl, G., Geissler, K., Keil, F., Krippl, P., Melchardt, T., Petzer, A., Rumpold, H., Sliwa, T., Wöhrer, S., Wölfler, A. & Gisslinger, H., 2019, in: WIENER KLINISCHE WOCHENSCHRIFT. 131, 1-2, S. 47
Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung
2018

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A. (Erstautor/-in), Steurer, M., Melchardt, T. (Co-Autor/-in), Weiss, L. (Co-Autor/-in), Gassner, F. J. (Co-Autor/-in), Zaborsky, N. (Co-Autor/-in), Geisberger, R. (Co-Autor/-in), Catakovic, K., Hartmann, T. (Co-Autor/-in), Pleyer, L. (Co-Autor/-in), Voskova, D., Thaler, J., Lang, A., Girschikofsky, M., Petzer, A. & Greil, R. (Letztautor/-in), 2018, in: ANNALS OF HEMATOLOGY . 97, 9, S. 1745
Publikation: Beitrag in Fachzeitschrift › Korrektur › Begutachtung

1 Quellenangabe (Web of Science)

Thomas Melchardt

Publikationen

Suchergebnisse

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.